Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR EBITDA Margin
EBITDA as a percentage of revenue.
Pharming Group N.V.NASDAQ: PHAR
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 1.5%
EBITDA Margin was 1.5% in Q1 FY2026, up 6.7 pp from a year earlier. On a trailing-twelve-month basis it was 10.7%, up 3.9 pp year over year. Over 3 fiscal years it narrowed by 7.9 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 14.0% for the fiscal year ending Dec 2026, up from 8.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 1.5%-3.4 pp QoQ
- Last fiscal yearDec 2025
- 8.4%+2.9 pp YoY
- LTMMar 2026
- 10.7%+3.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.7 pp | +1.6 pp | -5.0 pp |
| 1 year | +2.9 pp | +5.6 pp | +2.7 pp |
| 3 years | -7.9 pp | +10.9 pp | +18.8 pp |
| 5 years | +3.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 8.4%
- Year-over-year change
- +2.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.4% | +2.9pp |
| FY2024 | 2024-12-31 | 5.5% | +1.5pp |
| FY2023 | 2023-12-31 | 4.0% | -12.3pp |
| FY2022 | 2022-12-31 | 16.3% | -8.2pp |
| FY2021 | 2021-12-31 | 24.5% | — |
EBITDA Margin vs competitors
How PHAR compares with its peers on the latest reported figures
- PHAR's LTM Mar 2026 EBITDA Margin of 10.7% is the highest of the 8 companies compared; the peer median is -319.0%.
- Its year-over-year change of +3.9 pp is the 2nd highest of 7, against a peer median of -38.5 pp.
- Over three fiscal years its change of -7.9 pp compares with a peer median of +92.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 10.7% | +3.9 pp | -7.9 pp | |
| LTM Sep 2026 | -8.0% | -32.9 pp | +5.1 pp | |
| LTM Jun 2026 | -32.2% | -43.6 pp | +92.9 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Mar 2026 | -319.0% | -184.3 pp | +1328.5 pp | |
| LTM Mar 2026 | -511.5% | -539.6 pp | +799.5 pp | |
| LTM Mar 2026 | -581.9% | +549.6 pp | +308.9 pp | |
| LTM Mar 2026 | -8478.5% | — | -15524.4 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding PHAR) | -319.0% | -38.5 pp | +92.9 pp | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 225.46M | 205.62M | 245.32M | 307.75M | 377.18M |
| Cost of Revenue | 23.97M | 17.56M | 25.21M | 36.66M | 45.63M |
| Gross Profit | 201.49M | 188.06M | 220.1M | 271.09M | 331.56M |
| Gross Margin | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Research & Development | 79.78M | 52.53M | 68.91M | 86.1M | 98.08M |
| Selling, General & Admin | 54.56M | 68.85M | 87.5M | 102.74M | 117.44M |
| Operating Expenses | 186.12M | 169.83M | 225.49M | 280.02M | 309.75M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 10.76M |
| EBITDA | 55.3M | 33.53M | 9.88M | 16.89M | 31.7M |
| EBITDA Margin | 24.5% | 16.3% | 4.0% | 5.5% | 8.4% |
| Operating Income | 15.37M | 18.23M | (5.39M) | (8.93M) | 20.88M |
| Operating Margin | 6.8% | 8.9% | -2.2% | -2.9% | 5.5% |
| Interest Income | 59.99K | 85K | 3.53M | 5.92M | 2.56M |
| Interest Expense | 7M | 5.36M | 5.96M | 9.05M | 21.31M |
| Other Income / Expenses | 10.79M | (3.25M) | (6.63M) | 133.58K | (8.03M) |
| Income Before Tax | 26.16M | 14.99M | (12.01M) | (8.79M) | 12.88M |
| Pre-Tax Margin | 11.6% | 7.3% | -4.9% | -2.9% | 3.4% |
| Income Tax Expense | 8.03M | 1.31M | (1.46M) | 3.47M | 10.34M |
| Net Income | 18.13M | 13.67M | (10.55M) | (12.26M) | 2.86M |
| Net Margin | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% |
| EPS (Basic) | 0.23 | 0.17 | (0.14) | (0.18) | 0.04 |
| EPS (Diluted) | 0.21 | 0.16 | (0.14) | (0.18) | 0.04 |
| Weighted Avg Shares | 87.64M | 82.54M | 65.7M | 68.92M | 71.32M |
| Weighted Avg Shares (Diluted) | 87.64M | 84.28M | 65.7M | 68.92M | 71.32M |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.